Both 11b-hydroxysteroid dehydrogenase (11b-HSD1) inhibition and peroxisome proliferator-activated receptor-g (PPAR-g) agonism reduce liver and plasma lipids in rodents through partly distinct mechanisms. This study aimed to assess their additivity of action on liver and plasma lipids in a model of diet-induced steatosis. Rats were fed an obesogenic diet and were treated either with an 11b-HSD1 inhibitor (Compound A, 3 mg kg À1 day À1 ) or rosiglitazone (RSG, 5 mg kg À1 day À1 ) or both for 6 weeks. Compound A and RSG reduced liver steatosis and triglyceridemia, and did so additively when given in combination. The 11b-HSD1 inhibitor had no effect on serum adiponectin, but increased liver adiponectin receptor type 2 (Adipo-R2) mRNA levels. Conversely, RSG increased serum adiponectin, a likely mediator of its antisteatotic action, but had no effect per se on the Adipo-R2 expression. mRNA levels of representative genes of fatty acid oxidation tended to be increased by both compounds. The study shows that combined 11b-HSD1 inhibition and PPAR-g agonism additively reduce liver steatosis and triglyceridemia, which may eventually prove therapeutically useful.
Introduction
Defective handling of triglycerides (TG) in multiple tissues constitutes a major metabolic complication of at-risk obesity. Among others, liver steatosis has become increasingly worrisome, as the prevalence of obesity progresses, and hypertriglyceridemia is recognized as a risk factor for cardiovascular disease. 1 Local amplification of glucocorticoid (GC) action by the GC-activating enzyme, 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1), is gaining attention as one potential contributor to defective TG handling. 2 The enzyme is found in many tissues but is most strongly expressed in the liver. Overexpression of 11b-HSD1 is associated with fatty liver and an altered plasma lipid profile, whereas 11b-HSD1 deletion confers resistance to steatosis and hyperlipidemia in association with the increased expression of hepatic fatty acid oxidation genes. 2 We have recently shown that pharmacological 11b-HSD1 inhibition lowers triglyceridemia through reducing VLDL-TG (very-low-density lipoprotein-TG) secretion without affecting plasma TG clearance. 3 The peroxisome proliferator-activated receptor-g (PPAR-g) agonists, thiazolidinediones, are used clinically to improve insulin sensitivity. They also reduce liver steatosis and lipemia in rodent models, 4 and more modestly so in humans. 5 The antisteatotic action of PPAR-g agonism is thought to derive largely from PPAR-g action in adipose tissue, including redistribution of fat toward subcutaneous depots, reduced portal fatty acid delivery to the liver 4,5 and increased adiponectin secretion. 6 At least in rodents, triglyceridemia is also dramatically reduced by PPAR-g agonists, mainly due to enhanced clearance by adipose tissues.
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Both 11b-HSD1 inhibition and PPAR-g agonism therefore improve liver lipid metabolism and lipemia. The effect of their combination, however, has not been investigated to date. Combination therapy is deemed of clinical interest in the context of improving efficacy and minimizing side effects of individual compounds. Owing to their distinct mechanisms of action, but also because the two pathways might intersect, for instance at the level of major lipid modulators such as insulin and adiponectin action, we hypothesized that combination therapy would exert additive beneficial effects on diet-induced hepatic steatosis and hypertriglyceridemia.
Materials and methods

Animals and treatments
Thirty-two male Sprague-Dawley rats (65-75 g, Charles River Laboratories, St Constant, QC, Canada) were housed, cared for and handled as described, 3 ) and combined treatment (CA þ RSG at the above doses). This dose of CA does not affect food intake or weight gain and potently inhibits adipose and liver 11b-HSD1 activity. 3 The rosiglitazone dose was selected based on our pilot and other studies to elicit submaximal metabolic effects and allow for possible treatment additivity. Drugs were given for 6 weeks in the diet, with frequent adjustment for food intake/body weight. Then, after normal night feeding, food was removed at 0700 hours and rats were killed at 1300 hours.
Measurements and data analysis
Rats were killed by decapitation and serum was stored at À20 1C. The liver was excised and weighed, and samples were quick-frozen and stored at À80 1C. Triglyceride concentrations in serum and liver lipid extracts were measured enzymatically (Roche Diagnostics, Montreal, QC, Canada). In serum, glucose was determined by the glucose oxidase method, and insulin and adiponectin by radioimmunoassay (Linco Research, St Charles, MO, USA). The expression (mRNA) level of the major liver adiponectin receptor type 2 (Adipo-R2) and that of acyl-CoA oxidase 1 (ACO) and livertype carnitine palmitoyltransferase 1 (L-CPT1), key genes of peroxisomal and mitochondrial fatty acid oxidation, respectively, were determined by real-time quantitative PCR using the procedures described earlier, 3 with validated primers that are available upon request. Levels of mRNA are expressed as the number of copies per reaction. To control for sample loading, tissue samples were run in duplicate (variation o10%). Data (means±s.e.) were analyzed globally by analysis of variance and pairwise by Fisher's Protected Least Significant Difference test (significance set at Po0.05).
Results
Relative to the control group, the 11b-HSD1 inhibitor affected neither food intake nor weight or fat gain, whereas RSG given alone or in combination with CA exerted its well-established stimulatory effect on food intake ( þ 12%, Po0.05) and weight gain ( þ 15%, Po0.05), associated with increased fat accretion specifically in the subcutaneous depot (data not shown). Liver weight remained unaffected by either treatment (Table 1) . Fasting insulinemia and nonesterified fatty acid levels were robustly decreased by RSG, either alone or in combination, but not by CA alone, whereas glycemia was unaffected by either treatment (Table 1) . Liver and serum TG concentrations were reduced by CA (-26%, Figure 1a , and -33%, Figure 1b , respectively) as well as by RSG treatment (both -49%). Dual treatment further decreased liver TG (-64%) and tended to decrease serum TG slightly further (-60%) than either drug alone. CA had no significant effect on serum adiponectin, but increased liver Adipo-R2 mRNA ( þ 45%, Figure 1c) . RSG, whether given alone or with CA, increased serum adiponectin three-to four-fold, had no significant effect per se on liver Adipo-R2 mRNA levels, but prevented the CA-induced increase in receptor expression (Figure 1d ). Although CA tended to increase the expression of the fat oxidation genes ACO (P ¼ 0.08, Figure 1e ) and L-CPT1 (P ¼ 0.1, Figure 1f ), rosiglitazone did so significantly, with no additive effect of the combined treatment.
Discussion
This study shows that combined 11b-HSD1 inhibition and PPAR-g agonism exerted an additive beneficial effect on liver lipid accumulation, and tended to do so in the case of triglyceridemia. It is noteworthy that ingestive behavior, a major confounding factor with regard to lipid metabolism, was not affected by low-dose CA as is the case in 11b-HSD1 -/-mice 9 or with higher doses of various inhibitors reported earlier. 10, 11 This allowed assessment in this study of the direct, food intake-independent effects of 11b-HSD1 inhibition in the context of diet-induced obesity. In the present conditions, 11b-HSD1 inhibition did not alter fasting serum insulin levels, a crude but reliable index 11b-HSD1 inhibition, PPAR-c agonism and lipid metabolism M Berthiaume et al of insulin sensitivity. Improvement in insulin sensitivity by 11b-HSD1 inhibition has been reported in more severe models of obesity and type 2 diabetes, 10,11 although the effect could not be dissociated from the concomitant reduction in food intake and weight gain elicited by higher doses of inhibitors. With regard to PPAR-g agonism, RSG exerted its expected, powerful insulin-sensitizing action, reflected by a 50% reduction in fasting insulin concentrations, which was not further potentiated by the combined treatment. Whether 11b-HSD1 inhibition can improve insulin sensitivity under eucaloric conditions remains to be explored in finer detail. The reduction in triglyceridemia elicited by CA confirms our earlier study 3 and is in line with the improved metabolic profile reported in models with genetic 12 or pharmacologic 10,11 ablation of 11b-HSD1. Importantly, this study confirms 3 that 11b-HSD1 inhibition can alter triglyceridemia in high fat-fed rats independently from its anorectic action. We have reported that reduced hepatic VLDL-TG secretion explains the hypotriglyceridemic action of 11b-HSD1 inhibition, with no contribution from TG clearance. 3 This study also confirms the robust hypotriglyceridemic action of PPAR-g agonism, which is, in contrast to 11b-HSD1 inhibition, mainly due to a marked potentiation of TG clearance by adipose tissues in the rat. 7 It can be noted that the combination of CA and RSG tended to exert additive effects on triglyceridemia; however, as in the case of insulinemia, RSG alone was quite potent and may have precluded any further large reduction. The distinct modes of action of these compounds on triglyceridemia render their combination of particular interest for further investigation. Inhibition of 11b-HSD1 reduced liver TG content, extending earlier findings in 11b-HSD1 -/-mice 12 by showing the antisteatotic effect of pharmacologic 11b-HSD1 antagonism under eucaloric conditions. Such reduction in liver TG has been associated with increased liver expression of major genes of fatty acid oxidation. 3, 12 PPAR-g agonism also alleviates hepatic lipid accumulation, 4 as confirmed here.
The mechanisms of this PPAR-g action are thought to be indirect and to involve reduced provision of fatty acids and increased adiponectin production by adipose tissue, 6 with no apparent contribution from direct modulation of liver 11b-HSD1 activity, the latter being modestly increased as a compensatory response to its robust decrease in adipose tissue. 13 Adiponectin appears to act through AMPK (adenosine monophosphate-activated protein kinase)-mediated pathways to favor fatty acid oxidation and to reduce lipogenesis. 14 In this study, both compounds either alone or together tended to modestly, and non-additively, increase the mRNA levels of ACO and L-CPT1. These fragmentary findings support the involvement of fat oxidation in the antisteatotic action of the compounds; however, further research is clearly needed to establish their precise modes of interaction at the metabolic and molecular levels. Although 11b-HSD1 inhibition did not affect serum adiponectin levels, as might have been expected from genetically modified models, 15 this study unveiled an asyet unrecognized upregulation by 11b-HSD1 inhibition of the Adipo-R2 expression, which may enhance the beneficial biological activity of adiponectin in the liver. Increased Adipo-R2 mRNA is indeed associated with increased lipid oxidation and decreased liver fat content, likely because the receptor mediates the adiponectin-induced increase in AMPK. 14 The adiponectin-Adipo-R2 axis may therefore constitute one level at which 11b-HSD1 inhibition and PPAR-g agonism intersect. Interestingly, RSG prevented the increase in the Adipo-R2 expression elicited by 11b-HSD1 inhibition, possibly through feedback regulation by adiponectin itself. 16 It can be noted that the reduction in liver triglyceride content elicited by 11b-HSD1 inhibition and PPAR-g agonism was additive, underlining the high degree of plasticity of the liver in response to antisteatotic strategies. Such additivity may be favored by the fact that multiple mechanisms of action are contributory, thus avoiding saturation of any given pathway. As discussed above, the same likely applies to triglyceridemia, which also tended to 11b-HSD1 inhibition, PPAR-c agonism and lipid metabolism M Berthiaume et al be lowered in an additive manner by treatments. Although the establishment of the optimal therapeutic combination of compounds in the setting of specific phenotypes remains a significant challenge, the combinatorial approach explored in this study may prove useful in future strategies aimed at improving efficacy and reducing unwanted side effects of monotherapy.
